| Name | Title | Contact Details |
|---|
Sterling Pharmaceutical Services is a Maryville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Signify Health exists to drive more healthy, happy days at home. That`s why we`re committed to accelerating the movement to value-based care, transforming how care is paid for and delivered, and sharing accountability for driving better outcomes for the individuals and families we all serve. Today, Signify Health is privileged to impact the lives of millions of people every year. Our high-performance provider and community networks—which includes the nation`s largest field-based network of doctors and nurse practitioners—reaches and engages people anywhere in the U.S. With powerful analytics and clinical expertise, we support individuals` health journeys from the acute care facility to the ideal next site of care and all the way to a place of residence, helping them get home sooner and stay there longer. This is how we`re transforming a fragmented healthcare system into one that`s value-based, human-centered, and drives more healthy and happy days at home.
French Family-owned URGO Group is an international leading company and world expert in advanced wound care and selfcare. With its two divisions Urgo Medical and Urgo Consumer Healthcare, URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings that have proven their medical superiority through clinical studies, to address an increased need worldwide for the care of chronic wounds. It gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual well-being, cold and allergies. 3 300 collaborators participate in these missions in 22 countries, among which 10 industrial sites serve the needs of our clients.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.